A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
Conclusion: Preliminary data showed that BLU-554 in combination with CS1001 is safe and effective for treatment of patients with locally advanced or metastatic HCC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Diarrhoea | Drugs & Pharmacology | Hepatocellular Carcinoma | Immunotherapy | Investigational New Drugs | Liver | Liver Cancer | Skin | Study | Urology & Nephrology